Sacituzumab govitecan
- Status:
- Red
- Decision Date:
- November 2021
Comments
RED: TA819 - Sacituzumab govitecan for treating
unresectable triple-negative advanced breast cancer after 2 or more therapies. (Decision date - September 2022)Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again